Sanj K. Patel, President & CEO at SYNAGEVA BIOPHARMA CORP (GEVA), sold 38,395 shares at $51.64 ($2.0M) on 2013-04-04, disclosed to the SEC on 2013-04-05.
Scheduled sale ($2.0M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $51.09 | 10,206 | $521K | 26.7% |
| 2 | $52.55 | 4,358 | $229K | 11.7% |
| 3 | $53.37 | 1,500 | $80K | 4.1% |
| 4 | $54.44 | 400 | $22K | 1.1% |
| 5 | $50.12 | 18,580 | $931K | 47.6% |
| 6 | $50.72 | 2,151 |
| $109K |
| 5.6% |
| 7 | $51.64 | 1,200 | $62K | 3.2% |
| Total | $50.91 avg | 38,395 | $2.0M | 100% |
| Filing → |
| KNSA | SELL | 2026-04-08 | $364K | — | Filing → |
| KNSA | SELL | 2025-10-22 | $20.0M | — | Filing → |
| KNSA | SELL | 2025-05-28 | $4.6M | — | Filing → |